Novo Nordisk's Rybelsus has become the first oral GLP-1 agonist to pick up a regulatory approval for cardiovascular risk reduction, after getting a green light from the EMA's human medicine committee.

In retrospect, it makes sense that Daniel Hollander’s case brought tensions between Tucson police and the Pima County Attorney’s Office out into the open. Hollander put himself in a position to commit ...